Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 33 n° 348

Posts Tagged ‘Chief executive officer’

Merck Serono S.p.A. è concessionario esclusivo per la vendita in Italia di Eutirox®

Posted by fidest press agency su lunedì, 9 settembre 2013

Merck Serono S.p.A., affiliata italiana di Merck KGaA (Darmstadt, Germania) annuncia di avere iniziato, in data 1° luglio 2013, la commercializzazione del farmaco per il trattamento degli stati di ipotiroidismo Eutirox® (Levotiroxina sodica). Eutirox è presente sul mercato italiano dal 1981 (precedentemente commercializzato da Bracco su licenza Merck KGaA) ed è il trattamento che ha rivoluzionato l’approccio terapeutico all’ipotiroidismo (primo farmaco di sintesi chimica in un ambito tradizionalmente caratterizzato da farmaci di origine estrattiva). Le disfunzioni tiroidee sono di frequente riscontro: secondo stime dell’Organizzazione Mondiale della Sanità (OMS) ne sono affette circa un miliardo di persone in tutto il mondo. In particolare l’ipotiroidismo può essere riscontrato nel 6-17% della popolazione generale, con una maggiore prevalenza nelle donne e negli anziani. Uno studio del 2008 riporta un aumento dell’incidenza dell’ipotiroidismo, seppur con variazioni da paese a paese.La terapia sostitutiva con Levotiroxina è il trattamento standard per l’ipotiroidismo, ma è necessaria un’adeguata calibrazione giornaliera della dose per poter rispondere alle specifiche esigenze del singolo paziente.Eutirox® offre un’ampia varietà di dosaggi per il trattamento dell’ipotiroidismo (25/50/75/100/125/150/175/200 mcg), che consentono quindi la massima flessibilità posologica e, conseguentemente, una vera personalizzazione della terapia secondo le necessità del singolo paziente.Eutirox® è rimborsato dal Servizio Sanitario Nazionale, e detiene da lungo tempo la posizione di leadership sul mercato italiano. Il suo utilizzo è aumentato negli anni seguendo la tendenza di incremento dell’incidenza della patologia: nel 2012, secondo dati IMS, sono state vendute circa 19 milioni di confezioni, per un totale di quasi 1 miliardo di compresse.“Siamo particolarmente soddisfatti di aver inserito nel nostro portfolio prodotti uno dei farmaci Merck più conosciuti e diffusi – ha dichiarato Antonio Messina, Presidente ed Amministratore Delegato di Merck Serono S.p.A. Le patologie della tiroide sono in continuo aumento, ed Eutirox® rappresenta una soluzione terapeutica consolidata da più di trenta anni di largo utilizzo, nel corso dei quali ha contribuito a migliorare significativamente la qualità della  vita dei pazienti ipotiroidei”.

Posted in Cronaca/News, Medicina/Medicine/Health/Science | Contrassegnato da tag: , , , | Leave a Comment »

Edinburgh BioQuarter Announces Launch of i2eye Diagnostics

Posted by fidest press agency su mercoledì, 21 marzo 2012

An aerial view of Edinburgh BioQuarter

An aerial view of Edinburgh BioQuarter (Photo credit: Wikipedia)

Edinburgh, Scotland, (PRNewswire)Edinburgh BioQuarter today announced the launch of i2eye Diagnostics Limited, a company that will deliver the world’s first visual field analyser for patient groups whose visual field was previously impossible to test, including young children and vulnerable adults.i2eye Diagnostics has signed an agreement with the business investment syndicate Kelvin Capital and others for a significant strategic investment which will enable the company to complete the development of its world-first visual field testing instrument.Existing visual field testing instruments depend on the patient’s complete understanding, co-operation and considered feedback and involve keeping the patient’s head still, staring at a fixed point for several minutes. Innovative new technology, known as SVOP (Saccadic Vector Optokinetic Perimetry), harnesses the patient’s natural reactions to movement and light to analyse their visual field without any need for them to keep still, understand the test or give feedback to the tester. Visual field testing can now be performed on very young children as well as many elderly patients and other groups who could not previously be tested. The technology behind the i2eye visual field analyser was developed over five years by a clinical research team at the University of Edinburgh consisting of ophthalmologists, neurologists and medical physicists and led by Robert Minns, Professor of Paediatric Neurology. The new company has been formed with a management team working closely with the Business Creation team at Edinburgh BioQuarter. Peter Estibeiro, i2eye’s Chief Executive Officer, said: “Our instrument is a generation ahead of anything else currently on the market and has enormous potential. One of its first applications is in the monitoring and clinical management of children with brain tumours, where it can aid the decision making process potentially leading to a better outcome. The instrument will be on the market from the middle of 2012 and we are already seeing significant interest from leading paediatric medical centres around the world.” The value of the market targeted by i2eye is estimated at US$280 million in the United States, with markets of similar potential available in Europe and Asia. The company recently returned from exhibiting at the AAO (American Academy of Ophthalmology) Conference in Florida and experienced significant interest from practitioners and distributors spanning the globe.http://www.sdi.co.uk

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

32nd Annual Cowen Health Care Conference

Posted by fidest press agency su sabato, 3 marzo 2012

Novato, Calif. (GLOBE NEWSWIRE) — Raptor Pharmaceutical Corp. (“Raptor” or the “Company”) (Nasdaq:RPTP) today announced that the Company has been upgraded to trade on the NASDAQ Global Market. Shares of Raptor’s common stock began trading on the NASDAQ Global Market on February 29, 2012 and will continue to be traded under the ticker RPTP.
“As we continue to make progress towards potentially commercializing our first product, we see this as reinforcement that we have also progressed as a corporate entity since listing on the NASDAQ Capital Market,” said Kim R. Tsuchimoto, Chief Financial Officer, Treasurer and Secretary of Raptor. “We believe the move to the NASDAQ Global Market could bring increased market exposure and liquidity to our shares among those who recognize and appreciate our ability to meet the listing qualifications for the NASDAQ Global Market.”The Company also announced that Christopher M. Starr, Ph.D., the Company’s Chief Executive Officer, will present an overview of the company at the 32nd Annual Cowen Health Care Conference. Raptor’s presentation will take place at the Boston Marriott Copley Place on Wednesday, March 7th at 9:20am ET. A live audio webcast and 14-day archive of the Cowen presentation will be available at http://ir.raptorpharma.com/events.cfm
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) (“Raptor”) seeks to research, produce, and deliver medicines that improve life for patients with severe, rare disorders. Raptor currently has product candidates in clinical development designed to potentially treat nephropathic cystinosis, Non-alcoholic Steatohepatitis (“NASH”), Huntington’s Disease (“HD”), aldehyde dehydrogenase deficiency (“ALDH2”), and thrombotic disorder.Raptor’s preclinical programs are based upon bioengineered novel drug candidates and drug-targeting platforms derived from the human receptor-associated protein and related proteins that are designed to target cancer and infectious diseases.For additional information, please visit http://www.raptorpharma.com.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

The Latest Cross-Industry News from the Leading Research Source

Posted by fidest press agency su giovedì, 19 gennaio 2012

London Frost & Sullivan’s launch of the complimentary Growth, Innovation and Leadership (GIL) Community Newsletter is designed to provide executives industry news, market insights, best practices intelligence, identification of companies recognized by Frost & Sullivan analysts as best in class and a listing of live and virtual events. This unique portal of thought leadership and research information functions as a personalized Web site that can be customized based on the member’s needs and interests.The GIL Community Newsletter is a key component of Frost & Sullivan’s GIL Community dedicated to helping executives accelerate the growth of their company by providing career-enhancing ideas researched by Frost & Sullivan’s international team of expert analysts. Its design provides emerging market information, Mega Trends and technical advancement insights, as well as updates on the latest industry research, which keeps members informed and gives the insight needed to leverage growth in highly competitive markets.Highlights of the GIL Community Newsletter include multimedia content and easy navigation, as well as thought leadership to enhance business growth potential. This customized Web page will be continually updated to reflect the most recent industry insights, based on the parameters set by the user.“The mission of the GIL Community Newsletter is to drive visionary thinking by providing value to our subscribers,” said Vice President of Global Marketing and Chief Marketing Strategist, Bill Archer. “The content will enhance the users’ ability to gaining strategic knowledge and recommendations needed to grow their company and their careers.”
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company’s Growth Partnership Service provides the CEO and the CEO’s Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »